EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Elevated Serum hs-CRP Levels as an Inflammation Proxy in Heart Failure with Preserved Ejection Fraction: A Case-Control Study

Δάφνη - Άννα Ι-Φ. Δημητριάδου

Aristotle University of Thessaloniki · 01.01.2026

DOI: 10.26262/heal.auth.ir.374526 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2026. Verfasst von Δάφνη - Άννα Ι-Φ. Δημητριάδου.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The present study examines the utility of high-sensitivity CRP (hs-CRP) as an inflammatory biomarker in patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is now more widely thought of as a heterogeneous syndrome that frequently coexists with systemic inflammation, metabolic comorbidities, and endothelial dysfunction. The purpose of this study is to evaluate the diagnostic and prognostic value of hs-CRP in patients with HFpEF using a case-control design.

Methods

A total of 100 patients (60 HFpEF cases, 40 controls with mild cardiovascular background) were analyzed. Serum hs-CRP, NT-proBNP, creatinine, HbA1c, TSH and LDH were measured. Group comparisons were performed using Wilcoxon rank-sum and Chi-square tests. Logistic regression and ROC curve analysis assessed the predictive value of hs-CRP both in a univariate and multivariate model to adjust for other variables.

Results

The analysis revealed a pronounced difference in inflammatory status between the two groups. Patients with HFpEF exhibited significantly elevated levels of hs-CRP, with a median value of 8.71 mg/L, compared to 2.11 mg/L in the control group. This difference was statistically significant, indicating the association between systemic inflammation and HFpEF. The relationship between hs-CRP and HFpEF was further explored using logistic regression analysis, which identified hs-CRP as an independent predictor of disease status. Specifically, for every 1 mg/L increase in hs-CRP, the odds of having HFpEF increase by 21% (OR= 1.21, 95% CI: 1.07–1.36, p < 0.001) when accounting only for hs-CRP and by 17% (OR= 1.17, 95% CI: 1.01–1.36, p = 0.003), after adjusting for other clinical variables.

Conclusion

Elevated hs-CRP is strongly associated with HFpEF and may serve as an independent predictor of disease status or target for therapeutic approaches. Its inclusion in clinical care could support disease diagnosis and guide clinical management in patients with preserved ejection fraction heart failure.

Schlagwörter

heart failure with preserved ejection fractionhigh-sensitivity C-reactive proteinsystemic inflammationinflammatory markersNT-proBNPdisease diagnosisprognostic factorsendothelial dysfunctionmetabolic comorbidities

Zitieren

APA

Δημητριάδου, Δ. Ά. Ι. (2026). Elevated Serum hs-CRP Levels as an Inflammation Proxy in Heart Failure with Preserved Ejection Fraction: A Case-Control Study. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.374526

Vancouver

Δημητριάδου ΔΆΙ. Elevated Serum hs-CRP Levels as an Inflammation Proxy in Heart Failure with Preserved Ejection Fraction: A Case-Control Study. Aristotle University of Thessaloniki. 2026. doi:10.26262/heal.auth.ir.374526

BibTeX
@article{2026,
  author = {Δημητριάδου, Δάφνη - Άννα Ι-Φ.},
  title = {Elevated Serum hs-CRP Levels as an Inflammation Proxy in Heart Failure with Preserved Ejection Fraction: A Case-Control Study},
  journal = {Aristotle University of Thessaloniki},
  year = {2026},
  doi = {10.26262/heal.auth.ir.374526}
}
Kostenlos starten →